Content Spotlight
UAE accelerates push to become world’s first AI-native government
Opportunity around the adoption of Agentic AI opens new doors for health tech startups and enterprise vendors.
The business impact of artificial intelligence across drug discovery workflows.
The right competition creates an environment in which founders can test their proposition, build relationships and gain the visibility needed to move a business forward.
While investors chase urban mega-hospitals, the continent's real transformation is happening in thousands of rural clinics that no one is watching.
Key representatives at the Kenya Healthcare Federation outline how interoperability, sustainable financing, and smart regulation position Kenya as East Africa's digital health leader.
Digital Magazine
The official editorial partner of WHX Dubai and WHX Labs Dubai.
Content Spotlight
Opportunity around the adoption of Agentic AI opens new doors for health tech startups and enterprise vendors.
Where South Africa's healthcare industry meets, trades and does business
6-8 October 2026 | Johannesburg
Medical Technology
The US$3 million problem hiding in plain sight and why healthcare's digital friction is your most expensive invisible cost.
In conversation with Kostas Deligiannis, Zone President, EAGM, GE HealthCare.
In conversation with Betsabeh Madani-Hermann, Global Head of Research, Philips.
Medical Laboratory
The business impact of artificial intelligence across drug discovery workflows.
Explore the latest market insights, industry trends and strategic opportunities shaping healthcare and medical laboratories worldwide.
You are monitoring a CML patient in sustained MMR. Suddenly, the BCR-ABL result comes back negative — or unexpectedly positive. Sound familiar? Discordant molecular results are not just lab curiosities. They are clinical decision points that demand systematic investigation. 1. Pre-analytical pitfalls Contamination causes false positives. One CMR patient can show an unexpected 0.04% IS positivity — traced to amplicon contamination in the pipetting area. 2. Analytical blind spots 2025 ELN recommendation : Assays must detect all clinically relevant variants. 3. Interpretation gaps Reports must flag technical limitations: "RNA degradation suspected" or "Rare transcript not targeted." ✓ Process samples within 24 hours ✓ Validate control gene performance (assess Ct values) ✓ Confirm transcript coverage in atypical/relapsed cases ✓ Repeat unexpected results with fresh specimens ✓ Correlate molecular data with CBC and morphology ✓ Implement IS calibration and participate in EQA schemes Discordant BCR-...